Four things to know:
1. The healthcare technology company reported $7.7 billion in global revenue for the three-month period ending Jan. 24. That total represents annual growth of 2.3 percent, led by more than 4 percent growth in its restorative therapies business.
2. In the U.S., Medtronic saw revenue gains of just 0.5 percent, to $4 billion, representing about 52 percent of the company’s total revenue.
3. U.S. revenues were also led by about 4 percent growth in the restorative therapies group, while the minimally invasive therapies business reported 0.4 percent year-over-year growth. Both the cardiac and vascular group and diabetes group reported losses in revenue.
4. The quarter was a busy one for Medtronic: During the third quarter of its 2020 fiscal year, the company announced plans to acquire chronic pain treatment technology company Stimgenics, finalized its acquisition of artificial intelligence-enabled analytics software company Klue and formed a health IT partnership with Wilmington, Del.-based ChristianaCare.
More articles on health IT:
IBM Watson Health rolls out new clinical trial design software
Don’t be a ‘data pig’ & 2 more ways to maintain trust while collecting patient data
7 alerts, tools hospitals are adding to their EHRs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
